NAS:CRON (Canada) Also trade in: Canada Germany

Cronos Group Inc

$ 15.38 0.01 (0.07%)
Volume: 3,595,403 Avg Vol (1m): 7,692,420
Market Cap $: 5.13 Bil Enterprise Value $: 3.34 Bil
P/E (TTM): 55.88 P/B: 5.76
Earnings Power Value 5.66
Net Current Asset Value 2.05
Tangible Book 2.63
Projected FCF 0
Median P/S Value 14.22
Graham Number 4.05
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1014.80
Cash-To-Debt ranked lower than
93.25% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CRON: 1014.8
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.06, Med: 3.8, Max: 10000
Current: 1014.8
0.06
10000
Equity-to-Asset 0.36
Equity-to-Asset ranked higher than
79.06% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CRON: 0.36
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.85, Max: 0.97
Current: 0.36
0.36
0.97
Debt-to-EBITDA -0.13
Debt-to-EBITDA ranked higher than
70.51% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
CRON: -0.13
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -4.83, Med: -2.42, Max: 3.73
Current: -0.13
-4.83
3.73
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.42
DISTRESS
GREY
SAFE
Beneish M-Score -4.42
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 30.05%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -107.62
Operating Margin ranked higher than
55.06% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CRON: -107.62
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -384.66, Med: -83.48, Max: 540.55
Current: -107.62
-384.66
540.55
Net Margin % 2131.83
Net Margin ranked higher than
96.76% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CRON: 2131.83
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -214.8, Med: -98.02, Max: 2131.83
Current: 2131.83
-214.8
2131.83
ROE % 116.32
ROE ranked higher than
77.28% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CRON: 116.32
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -94.17, Med: -8.99, Max: 116.32
Current: 116.32
-94.17
116.32
ROA % 57.42
ROA ranked higher than
80.25% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CRON: 57.42
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -82.41, Med: -7.31, Max: 57.42
Current: 57.42
-82.41
57.42
ROC (Joel Greenblatt) % -14.60
ROC (Joel Greenblatt) ranked higher than
73.33% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CRON: -14.6
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -369.79, Med: -15.19, Max: 15.28
Current: -14.6
-369.79
15.28

» CRON's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CRON

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 3741
Compare BOM:500257 SZSE:002773 LSE:HIK SZSE:002001 SZSE:300142 NAS:TLRY SHSE:600535 OSTO:SOBI SHSE:600085 NAS:HZNP SZSE:300601 BOM:532321 NSE:DIVISLAB NYSE:CTLT OHEL:ORNAV TSE:4516 SZSE:000423 BSP:HYPE3 BOM:500124 SZSE:000999
Traded in other countries 7CI.Germany
Address 720 King Street West, Suite 320, Toronto, ON, CAN, M5V 2T3
Cronos Group Inc is a Canada-based cannabis company. Its principal activities comprise of production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. It sells dried cannabis and cannabis oils under its medical cannabis brand Peace Naturals. The company operates two wholly-owned licensed producers regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations namely, Peace Naturals and OGBC.

Ratios

Current vs industry vs history
PE Ratio (TTM) 55.88
PE Ratio ranked higher than
56.37% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
CRON: 55.88
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 53.4, Med: 478.82, Max: 810
Current: 55.88
53.4
810
Forward PE Ratio 69.44
Forward P/E ranked lower than
69.37% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
CRON: 69.44
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 55.88
PE without NRI ranked higher than
57.19% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
CRON: 55.88
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 53.4, Med: 478.82, Max: 810
Current: 55.88
53.4
810
Price-to-Owner-Earnings 13.31
Price-to-Owner-Earnings ranked lower than
100.00% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
CRON: 13.31
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 12.75, Med: 15.35, Max: 18.81
Current: 13.31
12.75
18.81
PB Ratio 5.76
PB Ratio ranked lower than
100.00% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CRON: 5.76
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.41, Med: 7.41, Max: 24.35
Current: 5.76
4.41
24.35
PS Ratio 224.73
PS Ratio ranked lower than
85.68% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CRON: 224.73
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 106.19, Med: 207.86, Max: 500
Current: 224.73
106.19
500
EV-to-EBIT -214.17
EV-to-EBIT ranked higher than
54.55% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CRON: -214.17
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -758.6, Med: -204.2, Max: -108
Current: -214.17
-758.6
-108
EV-to-EBITDA -245.46
EV-to-EBITDA ranked higher than
53.27% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CRON: -245.46
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -476.1, Med: -245, Max: 6423.2
Current: -245.46
-476.1
6423.2
EV-to-Revenue 233.47
EV-to-Revenue ranked lower than
86.04% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CRON: 233.47
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 106.7, Med: 211.2, Max: 660.1
Current: 233.47
106.7
660.1
Current Ratio 1.44
Current Ratio ranked lower than
76.26% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CRON: 1.44
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.1, Med: 3, Max: 52.75
Current: 1.44
0.1
52.75
Quick Ratio 1.42
Quick Ratio ranked lower than
84.56% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CRON: 1.42
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.1, Med: 2.32, Max: 47.46
Current: 1.42
0.1
47.46
Days Inventory 383.29
Days Inventory ranked lower than
59.21% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CRON: 383.29
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 241.98, Med: 598.52, Max: 823
Current: 383.29
241.98
823
Days Sales Outstanding 105.53
Days Sales Outstanding ranked lower than
65.97% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CRON: 105.53
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 70.5, Med: 96.76, Max: 105.53
Current: 105.53
70.5
105.53
Days Payable 1.00
Days Payable ranked higher than
99.34% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CRON: 1
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 1, Med: 1278.28, Max: 5820.27
Current: 1
1
5820.27

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -59.30
3-Year Share Buyback Rate ranked lower than
100.00% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
CRON: -59.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -112.1, Med: -62.5, Max: -59.3
Current: -59.3
-112.1
-59.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.85
Price-to-Tangible-Book ranked lower than
99.47% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
CRON: 5.85
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.88, Med: 6.44, Max: 19.84
Current: 5.85
0.88
19.84
Price-to-Median-PS-Value 1.08
Price-to-Median-PS-Value ranked lower than
51.82% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CRON: 1.08
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.59, Med: 1, Max: 1.67
Current: 1.08
0.59
1.67
Price-to-Graham-Number 3.80
Price-to-Graham-Number ranked higher than
59.04% of 481 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
CRON: 3.8
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.83, Med: 8.16, Max: 23.76
Current: 3.8
0.83
23.76
Earnings Yield (Joel Greenblatt) % -0.43
Earnings Yield (Greenblatt) ranked higher than
70.01% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CRON: -0.43
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -0.9, Med: -0.5, Max: -0.1
Current: -0.43
-0.9
-0.1

More Statistics

Revenue (TTM) (Mil) $ 14.48
EPS (TTM) $ 0.28
Beta 0
Volatility % 118.09
52-Week Range $ 5.61 - 25.1
Shares Outstanding (Mil) 334.09

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y